Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Garrett

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Molecular Cancer Therapeutics|August 25, 2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trialGeorge R Simon, Richard M Lush, Jana Gump, et al.
Annals of Surgery|September 13, 2012
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastasesAndreas Andreou, Scott Kopetz, Dipen M Maru, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 18, 2014
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?David R Fogelman, Holly Holmes, Khalil Mohammed, et al.
Annals of Surgery|May 10, 2013
A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancerMichael A Morse, Donna Niedzwiecki, John L Marshall, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Molecular Cancer Therapeutics|August 25, 2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trialGeorge R Simon, Richard M Lush, Jana Gump, et al.
Annals of Surgery|September 13, 2012
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastasesAndreas Andreou, Scott Kopetz, Dipen M Maru, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 18, 2014
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?David R Fogelman, Holly Holmes, Khalil Mohammed, et al.
Annals of Surgery|May 10, 2013
A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancerMichael A Morse, Donna Niedzwiecki, John L Marshall, et al.
Pageof 3